NEW ROCHELLE, N.Y.--(BUSINESS WIRE)--Jan. 17, 2006--An adenoviral-based vector containing the gene for human pigment epithelium-derived factor (PEDF) showed evidence of being able to stop disease progression when injected directly into the eyes of patients with neovascular age-related macular degeneration, according to the results of a phase I clinical trial to be published in the February 2006 issue (Volume 17, Number 2) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper has been published online ahead of print and can be viewed at www.liebertpub.com/hum. These promising results suggest that adenoviral vector-mediated ocular gene transfer represents a viable approach to treating ocular disorders such as age-related macular degeneration (AMD), which is one of the most common causes of severe vision loss.
